Company Overview of Viamet Pharmaceuticals, Inc.
Viamet Pharmaceuticals, Inc., a biotechnology company, discovers and develops inhibitors of validated metalloenzymes. It provides Metallobase, a database of metalloenzymes and known metalloenzyme inhibitors; Metallophiles, that are metal-binding groups; and Metallophile Indices, which are a series of proprietary, in silico predictive tools for the rapid selection of optimal Metallophiles. The company also develops small molecule compounds that exploit validated metalloenzyme targets in the fields of inflammation, infectious disease, and oncology. The company was formerly known as Hephistics, Inc. Viamet Pharmaceuticals, Inc. was incorporated in 2004 and is based in Morrisville, North Carolin...
2250 Perimeter Park Drive
Morrisville, NC 27560
Founded in 2004
Key Executives for Viamet Pharmaceuticals, Inc.
Chief Business and Financial Officer
Chief Development Officer
Compensation as of Fiscal Year 2014.
Viamet Pharmaceuticals, Inc. Key Developments
Viamet Announces Appointment of Amir Tavakkol as Chief Development Officer
Jul 22 14
Viamet Pharmaceuticals, Inc. announced the appointment of Amir Tavakkol, Ph.D., as Chief Development Officer. Dr. Tavakkol brings over 25 years of experience in pharmaceuticals, consumer healthcare and academia, including substantial expertise in the clinical development of novel antifungal products for superficial as well as systemic indications. Dr. Tavakkol will have significant responsibility for the management of Viamet's clinical programs, including the ongoing clinical development of VT-1161, the Company's lead novel, oral antifungal compound. Prior to joining Viamet, Dr. Tavakkol most recently served as Senior Vice President of Clinical Development & Operations at Topica Pharmaceuticals Inc.
Viamet Reports Additional Positive Interim Results of Phase 2 Studies of VT-1161 with Moderate to Severe Interdigital Tinea Pedis
Jul 10 14
Viamet Pharmaceuticals, Inc. reported additional positive interim results from its ongoing Phase 2a study of VT-1161, the Company's lead novel, oral antifungal compound, in patients with moderate to severe interdigital tinea pedis, commonly known as athlete's foot. The additional data being reported now are for the higher dose of VT-1161 in the study. These data provide additional strong evidence of clinical antifungal activity and a favorable safety profile for VT-1161 in treating human infections due to dermatophytes. Based on these positive results, the company expects to begin Phase 2b clinical trials for VT-1161 in patients with onychomycosis in the second half of 2014. This Phase 2a study is an exploratory, dose-ranging, proof of concept trial that enrolled 50 patients with moderate to severe tinea pedis across three VT-1161 dose groups and a placebo group. Patients were randomized and treated for a period of 14 days. The Company's intent in conducting this clinical trial is to establish proof of concept that VT-1161 is safe and clinically active in treating human infections due to dermatophytes. Because the dermatophyte pathogens are typically the same in patients with tinea pedis as in patients with onychomycosis, the Company believes that the results in this Phase 2a tinea pedis trial will be indicative of likely antifungal activity in its planned Phase 2b onychomycosis clinical trial. A test-of-cure visit was conducted on Day 42 of the study, at which time both clinical and mycologic endpoints were evaluated. Effective clinical cure was based upon an improvement in six clinical signs and symptoms. Mycologic cure was defined as a negative fungal stain and culture. Effective therapeutic cure was defined as both effective clinical cure and mycologic cure. Through the test-of-cure visit on Day 42, VT-1161 was again found to be well tolerated with no serious adverse events reported. One patient in the high-dose VT-1161 group discontinued treatment due to a rash. There were no clinically relevant changes noted in vital signs, physical exam findings, electrocardiograms, or chemistry, hematology or urinalysis parameters.
Viamet Reports Positive Interim Results of Phase 2 Study of VT-1161
Feb 18 14
Viamet Pharmaceuticals Inc. reported positive interim results from an ongoing Phase 2 study of VT-1161, the company's novel oral antifungal compound, in patients with moderate to severe acute vulvovaginal candidiasis (AVVC). This study is intended as a precursor to a Phase 2b study in patients with recurrent vulvovaginal candidiasis (RVVC). VT-1161 is an inhibitor of the fungal metalloenzyme CYP51, the target of the current triazole antifungals, but is from a novel chemical class that was rationally designed by Viamet to provide a superior efficacy profile and to avoid many of the side effects that characterize these agents. The AVVC study will enroll approximately 48 patients in three VT-1161 oral dose groups versus oral fluconazole, the current clinical standard of care for moderate to severe AVVC. In the initial portion of the study, patients were enrolled in the low-dose VT-1161 group, the mid-dose VT-1161 group and the fluconazole control group. Both clinical and mycologic endpoints were evaluated at the test-of-cure visit on Day 28. Effective clinical cure was based upon an improvement in six clinical signs and symptoms of AVVC. Mycologic cure was defined as a negative fungal culture. Effective therapeutic cure was defined as both effective clinical cure and mycologic cure.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|